|Year : 2015 | Volume
| Issue : 2 | Page : 114-118
Comparative efficacy of methylphenidate and atomoxetine in oppositional defiant disorder comorbid with attention deficit hyperactivity disorder
Jasmin Garg, Priti Arun, BS Chavan
Department of Psychiatry, Government Medical College and Hospital, Sector 32, Chandigarh, India
|Date of Submission||30-Jul-2014|
|Date of Acceptance||30-Sep-2014|
|Date of Web Publication||18-May-2015|
Department of Psychiatry, 5th Level, D Block, Government Medical College and Hospital, Sector 32, Chandigarh
Source of Support: None, Conflict of Interest: None
Clinical trial registration CTRI/2011/08/001981
| Abstract|| |
Background: Oppositional defiant disorder (ODD) is frequently comorbid with attention deficit hyperactivity disorder (ADHD) and is associated with substantial functional impairments. Methylphenidate and atomoxetine are well-established drugs for the management of ADHD. Some studies from Western countries have reported these drugs to be effective in the management of ODD comorbid with ADHD. This study aimed to assess if methylphenidate and atomoxetine are efficacious in treating Indian children with ODD comorbid with ADHD. Subjects and Methods: In this prospective, open-label study, 37 patients of age 6-14 years with a diagnosis of ODD comorbid with ADHD randomly received either methylphenidate (dose 0.2-1 mg/kg/day) or atomoxetine (dose 0.5-1.2 mg/kg/day) for 8 weeks. Improvements in ADHD and ODD symptoms were assessed using Vanderbilt ADHD diagnostic parent rating scale (VADPRS). Results: At 8 weeks, there were statistically significant improvements in both ADHD and ODD symptoms in both methylphenidate and atomoxetine groups, as per VADPRS. The improvements produced and tolerability was comparable in the two groups. 80% of the patients from methylphenidate group and 64.3% patients from atomoxetine group ceased to fulfill the criteria for the presence of ODD at 8 weeks. Conclusions: Methylphenidate and atomoxetine are effective in the treatment of ODD comorbid with ADHD in short duration.
Keywords: Atomoxetine, attention deficit hyperactivity disorder, methylphenidate, oppositional defiant disorder
|How to cite this article:|
Garg J, Arun P, Chavan B S. Comparative efficacy of methylphenidate and atomoxetine in oppositional defiant disorder comorbid with attention deficit hyperactivity disorder. Int J App Basic Med Res 2015;5:114-8
|How to cite this URL:|
Garg J, Arun P, Chavan B S. Comparative efficacy of methylphenidate and atomoxetine in oppositional defiant disorder comorbid with attention deficit hyperactivity disorder. Int J App Basic Med Res [serial online] 2015 [cited 2021 Jul 28];5:114-8. Available from: https://www.ijabmr.org/text.asp?2015/5/2/114/157162
| Introduction|| |
Oppositional defiant disorder (ODD) consists of recurrent uncooperative, disobedient, and hostile behavior which is not accounted for by the developmental stage of the child. It is defined in DSM-IV-TR as an enduring pattern of negativistic, defiant, and disruptive behavior toward authority figures. It must be present for more than 6 months and must not be caused by psychosis or a mood disorder, and the behavior must negatively impact the child's social, academic, or occupational functioning. It does not include the most aggressive aspects of conduct disorder which is directed toward people, animals and property.  Negativistic and defiant behaviors are expressed by persistent stubbornness, resistance to directions, and unwillingness to compromise, give in or negotiate with adults and peers. It may also involve deliberate and persistent testing of limits, usually by ignoring orders, arguing, and failing to accept blame for misbehavior. ODD is among the most common mental health conditions in childhood. The prevalence of ODD in the general population has been reported to be between 2% and 16%. It has been estimated that around 60% of patients with ODD will develop conduct disorder and will have high risk for substance abuse.  Children with ODD have substantially impaired relationships with parents, teachers, and peers. These children are not only impaired in comparison with their peers, but they also show greater social impairment than do children with bipolar disorder, depression, and anxiety disorders. 
Oppositional defiant disorder has a high co-occurrence with attention deficit hyperactivity disorder (ADHD). In 35-65% of patients with ADHD, ODD is also part of the clinical picture.  Children with ADHD and comorbid ODD tend to experience more severe ADHD symptoms, greater functional impairment and poor quality of life than children with ADHD alone.  This means that families are under high levels of stress, dealing with several difficult behaviors.
Several studies from Western countries have shown that psychostimulants like methylphenidate are effective in ODD patients with comorbid ADHD. In a meta-analysis of 28 studies, it was reported that stimulants are effective in overt and covert aggression-related behaviors in ADHD in a short-term.  Atomoxetine is a selective norepinephrine reuptake inhibitor approved for the treatment of ADHD since 2002.  Atomoxetine has also been used in the management of ODD comorbid with ADHD as some studies have evaluated its efficacy in a short term. ,,,,, These studies have reported mixed results about improvements in ODD symptoms. However, there are no data from India. Hence, the present study was carried out to find out if methylphenidate and atomoxetine are efficacious in the treatment of ODD comorbid with ADHD.
| Subjects and Methods|| |
Patients were inducted from those attending the Child Guidance Clinic of a tertiary care hospital in North India from October 2010 to May 2012. This study is a subset of another trial which aimed to assess the efficacy of methylphenidate and atomoxetine in symptom reduction of ADHD. Patients of 6-14 years age, with a diagnosis of ADHD, according to DSM-IV-TR were recruited for the trial. These patients were administered the Vanderbilt ADHD Diagnostic Parent Rating Scale (VADPRS)  to screen for the presence of comorbid ODD. The patients with the diagnosis of ODD with comorbid ADHD were taken up in the present study. It was a prospective, randomized, open-label study. Children were brought by parents or referred by school to the Child Guidance Clinic. Patients with a history of nonresponse or adverse drug reactions to either methylphenidate or atomoxetine and the patients who had taken any medication for ADHD in the past 1-month were excluded. In addition, the patients with a history of heart disease, seizures, pervasive developmental disorder, substance abuse, mental retardation, or tic disorder were also excluded. Before initiating treatment, electrocardiogram was performed for each patient to rule out any cardiac abnormality.
The patients were allotted to two groups as per computer-generated table of random numbers (group A and group B). Patients of group A received immediate release tablet methylphenidate (once or twice daily) and group B received tablet atomoxetine (once or twice daily). The initial sample consisted of 69 ADHD patients randomized into methylphenidate and atomoxetine groups. Of 69 patients with ADHD, 15 from methylphenidate group and 22 from atomoxetine group fulfilled the criteria for the presence of comorbid ODD, and these were included in the analysis of the present study [Figure 1].
Patients were started on tablet methylphenidate (immediate-release) 5 mg OD or tablet atomoxetine 10 mg OD on their first visit. Efforts were made to increase the dose of methylphenidate up to 1 mg/kg/day and of atomoxetine up to 1.2 mg/kg/day once or twice daily depending upon the response and tolerability. Weekly increments of 5 mg were tried for both methylphenidate and atomoxetine. Patients were assessed at baseline and once weekly till 8 weeks. The patients who could not come for weekly follow-up, were assessed fortnightly. On each visit, improvement in symptoms of ADHD and ODD was assessed by VADPRS. The various side effects were noted on each assessment on the Adverse Events Checklist prepared for the study. Patients who developed intolerable side effects were taken out of the study. They were then managed as per standard departmental protocol. Written and informed consent was obtained from both parents/guardians and the children. Clearance was sought from the ethics committee of the institution. The trial was registered in clinical trial registry, India with registration number CTRI/2011/08/001981.
Data were analyzed using SPSS (version 16.0. Chicago, SPSS Inc., 2007), and it was represented in mean and (standard deviation). Significance level was P < 0.05 (two-tailed). Fisher's exact test and Chi-square test were used to compare categorical variables. Mann-Whitney test and Wilcoxon signed rank test were used for analysis of nonparametric data.
| Results|| |
At baseline, methylphenidate and atomoxetine groups were comparable with regard to mean age and sex distribution. In both the groups, males outnumbered the females for the presence of ODD, the combined type of ADHD was the most common, followed by inattention type and hyperactive/impulsive type. Chi-square test was used to assess whether the two groups were comparable with respect to the number of patients with any of the three types of ADHD, and no significant difference was found. Patients were also screened for the presence of depression and anxiety, but none fulfilled the criteria for the same. The baseline VADPRS total score and VADPRS subscale scores (inattention, hyperactivity and ODD) were comparable between the two groups on the Mann-Whitney test [Table 1].
Five patients in the methylphenidate group and 8 in the atomoxetine group dropped out in the course of study. Various reasons for drop outs are shown in [Figure 1]. There was no statistically significant difference between the reasons for drop-outs between the two groups on the Chi-square test (P = 0.349). The adverse effects which lead to drop out were reduction in appetite, headache, irritability in both the groups; drowsiness and sadness in the atomoxetine group and fatigue in the methylphenidate group.
Improvement in ADHD symptoms and ODD symptoms as measured on VADPRS score was assessed using Wilcoxon signed rank test as data was not normally distributed. Highly significant difference was found in VADPRS scores in both the groups after 8 weeks. The mean VADPRS (total and subscales) scores were compared in methylphenidate and atomoxetine groups using Mann-Whitney test at 8 weeks and no statistically significant difference was found [Table 2].
At 8 weeks, according to VADPRS, 8 children out of 10 (or 80%) ceased to fulfill the criteria for the presence of ODD in the methylphenidate group. Similarly, in the atomoxetine group, out of 14 children, 9 children (or 64.3%) ceased to have symptoms of ODD at 8 weeks [Figure 1].
The average dose administered at 8 weeks was 15.41 mg/day (or 0.490 mg/kg/day) in methylphenidate group and 17.21 mg/day (or 0.672 mg/kg/day) in atomoxetine group. According to the adverse effects checklist prepared for the study, a total of 7 (46.6%) patients from methylphenidate group and 12 (54.5%) from atomoxetine group developed some side effect during the course of the study. The various adverse effects reported by the patients in two groups are listed in [Table 3]. These were compared between both groups, and no significant difference was found on the Chi-square test. In addition, one case each reported insomnia and pain abdomen in the methylphenidate group. Similarly one case each reported nausea, vomiting, and sadness in the atomoxetine group.
|Table 3: Comparison of adverse effects in methylphenidate and atomoxetine groups |
Click here to view
| Discussion|| |
In the present study, ODD was present in 53% of patients with ADHD. Majority of the children were males, the similar findings have been reported in earlier studies.  The results showed that both methylphenidate and atomoxetine were highly effective in reducing the symptoms of ODD. Earlier short-term placebo-controlled trials of methylphenidate for ODD comorbid with ADHD have also shown it to be effective. ,,, Some previous studies found atomoxetine to be superior than placebo in improving ODD symptoms, ,, while others did not. ,, The dose of atomoxetine administered to the patients in the present study was well within the prescribed limit for management of ADHD.  It was unlike the findings of a previous study which reported that higher dose of atomoxetine was required to produce improvements in patients with ADHD comorbid with ODD, than those with ADHD alone. 
In this study, 80% of the patients in the methylphenidate group failed to fulfill the criteria for diagnosis of ODD at the conclusion of the study. This was also concordant with findings of an earlier study where methylphenidate treatment in the short-term lead to remission of ODD in 9 out of 10 children.  In the atomoxetine group, 64.3% patients had remission of symptoms of ODD. The remission of ODD has not been directly evaluated in previous placebo-controlled trials of atomoxetine. The two drugs produced comparable improvements in symptoms of ODD. Both the drugs were equally tolerated in relation to the development of adverse effects. The rate of occurrence of adverse effects was also consistent with results of some previous comparative trials of methylphenidate and atomoxetine in ADHD. 
This study had certain limitations. It was an open label trial, and placebo arm was not included due to ethical reasons. The improvement produced by both the drugs in ODD symptoms might imply that defiant and hostile behaviors were an integral part of ADHD and improvement in ADHD also led to improvement in ODD symptoms. Furthermore, the follow-up period was short, and it needs to be seen whether improvement in ODD symptoms sustains over the long period.
Nevertheless, this is the first study from India comparing efficacy of atomoxetine and methylphenidate in ODD comorbid with ADHD. The study indicates that ODD comorbid with ADHD shows considerable improvement with both methylphenidate and atomoxetine and symptoms of ODD remits in majority with short duration of treatment. Both drugs had comparable efficacy and good tolerability.
| Acknowledgement|| |
Cost of medication was borne by Government Medical College and Hospital, Sector 32, Chandigarh.
| References|| |
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorder. 4 th
ed. Text Revision. Washington DC: American Psychiatric Association; 2000.
Turgay A. Psychopharmacological treatment of oppositional defiant disorder. CNS Drugs 2009;23:1-17.
Hamilton SS, Armando J. Oppositional defiant disorder. Am Fam Physician 2008;78:861-6.
Rader R, McCauley L, Callen EC. Current strategies in the diagnosis and treatment of childhood attention-deficit/hyperactivity disorder. Am Fam Physician 2009;79:657-65.
Kuhne M, Schachar R, Tannock R. Impact of comorbid oppositional or conduct problems on attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 1997;36:1715-25.
Connor DF, Glatt SJ, Lopez ID, Jackson D, Melloni RH Jr. Psychopharmacology and aggression. I: A meta-analysis of stimulant effects on overt/covert aggression-related behaviors in ADHD. J Am Acad Child Adolesc Psychiatry 2002;41:253-61.
Unni JC. Atomoxetine. Indian Pediatr 2006;43:603-6.
Kaplan S, Heiligenstein J, West S, Busner J, Harder D, Dittmann R, et al.
Efficacy and safety of atomoxetine in childhood attention-deficit/hyperactivity disorder with comorbid oppositional defiant disorder. J Atten Disord 2004;8:45-52.
Biederman J, Spencer TJ, Newcorn JH, Gao H, Milton DR, Feldman PD, et al.
Effect of comorbid symptoms of oppositional defiant disorder on responses to atomoxetine in children with ADHD: A meta-analysis of controlled clinical trial data. Psychopharmacology (Berl) 2007;190:31-41.
Bangs ME, Hazell P, Danckaerts M, Hoare P, Coghill DR, Wehmeier PM, et al.
Atomoxetine for the treatment of attention-deficit/hyperactivity disorder and oppositional defiant disorder. Pediatrics 2008;121:e314-20.
Newcorn JH, Spencer TJ, Biederman J, Milton DR, Michelson D. Atomoxetine treatment in children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder. J Am Acad Child Adolesc Psychiatry 2005;44:240-8.
Dell'Agnello G, Maschietto D, Bravaccio C, Calamoneri F, Masi G, Curatolo P, et al.
Atomoxetine hydrochloride in the treatment of children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder: A placebo-controlled Italian study. Eur Neuropsychopharmacol 2009;19:822-34.
Dittmann RW, Schacht A, Helsberg K, Schneider-Fresenius C, Lehmann M, Lehmkuhl G, et al.
Atomoxetine versus placebo in children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder: A double-blind, randomized, multicenter trial in Germany. J Child Adolesc Psychopharmacol 2011;21:97-110.
Wolraich ML, Lambert W, Doffing MA, Bickman L, Simmons T, Worley K. Psychometric properties of the Vanderbilt ADHD diagnostic parent rating scale in a referred population. J Pediatr Psychol 2003;28:559-67.
Gadow KD, Nolan EE, Sverd J, Sprafkin J, Schneider J. Methylphenidate in children with oppositional defiant disorder and both comorbid chronic multiple tic disorder and ADHD. J Child Neurol 2008;23:981-90.
Ter-Stepanian M, Grizenko N, Zappitelli M, Joober R. Clinical response to methylphenidate in children diagnosed with attention-deficit hyperactivity disorder and comorbid psychiatric disorders. Can J Psychiatry 2010;55:305-12.
Bukstein OG, Kolko DJ. Effects of methylphenidate on aggressive urban children with attention deficit hyperactivity disorder. J Clin Child Psychol 1998;27:340-51.
Sinzig J, Döpfner M, Lehmkuhl G, German Methylphenidate Study Group, Uebel H, Schmeck K, et al.
Long-acting methylphenidate has an effect on aggressive behavior in children with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 2007;17:421-32.
Serra-Pinheiro MA, Mattos P, Souza I, Pastura G, Gomes F. The effect of methylphenidate on oppositional defiant disorder comorbid with attention deficit/hyperactivity disorder. Arq Neuropsiquiatr 2004;62:399-402.
Hanwella R, Senanayake M, de Silva V. Comparative efficacy and acceptability of methylphenidate and atomoxetine in treatment of attention deficit hyperactivity disorder in children and adolescents: A meta-analysis. BMC Psychiatry 2011;11:176.
[Table 1], [Table 2], [Table 3]
|This article has been cited by|
||Blood Lead Levels and Associated Sociodemographic Factors among Children Aged 3 to 14 Years Living near Zinc and Lead Mines in Two Provinces in Vietnam
| ||Thi Giang Hoang,Quang Phuc Tran,Van Tung Lo,Ngoc Hai Doan,Thu Ha Nguyen,Minh Khue Pham,Wangjian Zhang |
| ||BioMed Research International. 2021; 2021: 1 |
|[Pubmed] | [DOI]|
||Efficacy and Safety of Medication for Attention-Deficit Hyperactivity Disorder in Children and Adolescents with Common Comorbidities: A Systematic Review
| ||Noa Tsujii,Masahide Usami,Noriyuki Naya,Toshinaga Tsuji,Hirokazu Mishima,Junko Horie,Masakazu Fujiwara,Junzo Iida |
| ||Neurology and Therapy. 2021; |
|[Pubmed] | [DOI]|
||The Greek Version of the Vanderbilt ADHD Diagnostic Parent Rating Scale for Follow-up Assessment in Prepubertal Children with ADHD
| ||August Kapogiannis,Gerasimos Makris,Christina Darviri,Artemios Artemiadis,Dionysios Klonaris,Sofia Tsoli,Theodora Bachourou,Charikleia Stefanaki,Katerina Papanikolaou,George Chrousos,Panagiota Pervanidou |
| ||International Journal of Disability, Development and Education. 2020; : 1 |
|[Pubmed] | [DOI]|
||A Randomized, Double-Blind, Placebo-Controlled, Two-Way Crossover Clinical Trial of ORADUR-Methylphenidate for Treating Children and Adolescents with Attention-Deficit/Hyperactivity Disorder
| ||Yu-Shu Huang,Chin-Bin Yeh,Chin-Hung Chen,Chi-Yung Shang,Susan Shur-Fen Gau |
| ||Journal of Child and Adolescent Psychopharmacology. 2020; |
|[Pubmed] | [DOI]|
||Blood lead, bone lead and child attention-deficit-hyperactivity-disorder-like behavior
| ||Yanfen Lin,Lihua Huang,Jian Xu,Aaron J. Specht,Chonghuai Yan,Hongquan Geng,Xiaoming Shen,Linda H. Nie,Howard Hu |
| ||Science of The Total Environment. 2019; 659: 161 |
|[Pubmed] | [DOI]|
||Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents - assessment of adverse events in non-randomised studies
| ||Ole Jakob Storebø,Nadia Pedersen,Erica Ramstad,Maja Laerke Kielsholm,Signe Sofie Nielsen,Helle B Krogh,Carlos R Moreira-Maia,Frederik L Magnusson,Mathilde Holmskov,Trine Gerner,Maria Skoog,Susanne Rosendal,Camilla Groth,Donna Gillies,Kirsten Buch Rasmussen,Dorothy Gauci,Morris Zwi,Richard Kirubakaran,Sasja J Håkonsen,Lise Aagaard,Erik Simonsen,Christian Gluud |
| ||Cochrane Database of Systematic Reviews. 2018; |
|[Pubmed] | [DOI]|
||ADHD research in India: A narrative review
| ||Pooja Patnaik Kuppili,Harshini Manohar,Raman Deep Pattanayak,Rajesh Sagar,Balaji Bharadwaj,Preeti Kandasamy |
| ||Asian Journal of Psychiatry. 2017; 30: 11 |
|[Pubmed] | [DOI]|
||A strategy for increasing the efficiency of psychopharmacological treatment of hyperkinetic behavior disorder with pantogam
| ||T. A. Kupriyanova,E. V. Koren,N. N. Alabusheva |
| ||Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2017; 117(11): 75 |
|[Pubmed] | [DOI]|
||Clinical Practice Guidelines for Major Comorbid Disorders with Attention-Deficit Hyperactivity Disorder
| ||Gi Jung Hyun,Bongseog Kim,Bung-Nyun Kim,Johanna Inhyang Kim,Jeong Ha Park,Geon Ho Bahn,Moon-Soo Lee,Soyoung Irene Lee,Young Sik Lee,Doug Hyun Han |
| ||Journal of Korean Neuropsychiatric Association. 2016; 55(4): 343 |
|[Pubmed] | [DOI]|